NextCure, Inc.
9000 Virginia Manor Rd. Suite 200
Beltsville
MD
20705
United States
Tel: (240)399-4900
Website: https://www.nextcure.com/
Email: Info@NextCure.com
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Cancer is a complex disease where cells in the tumor microenvironment promote tumor progression, immune evasion and suppression of anti-tumor immune responses. While therapies targeting inhibitory or immune checkpoint molecules have shown important success in many cancers, not all patients benefit from these therapies (non-responders), and many develop resistance after initial treatment. NextCure is identifying novel tumor-specific interactions and mechanisms of immune regulation to generate a sustainable product pipeline to address these patients in need.
NextCure brings significant experience and innovation in cancer immunology. The company’s FIND-IOTM technology provides a large repertoire of function-based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. We are using this important knowledge to rapidly develop and advance novel biologics that impact suppressive myeloid cell populations, T cell subsets, and other cell populations within the tumor microenvironment to restore anti-tumor activity and improve clinical response rates and outcomes for patients.
Stock Symbol: NXTC
Business Spotlight - Nextcure
85 articles about NextCure, Inc.
-
NextCure to Present at the JMP Securities Life Sciences Conference - May 09, 2023
5/9/2023
NextCure, Inc. announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
-
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
5/4/2023
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases provided a business update and reported first quarter 2023 financial results.
-
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
3/2/2023
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.
-
NextCure to Present at SVB Securities Global Biopharma Conference
2/7/2023
NextCure, Inc. today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
-
NextCure to Present at Upcoming Investor Conferences
11/22/2022
NextCure, Inc. today announced that it will present at the following investor conferences.
-
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
11/15/2022
NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
-
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
11/7/2022
NextCure, Inc today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 clinical trial of NC762.
-
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
11/3/2022
NextCure, Inc. (Nasdaq: NXTC) today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans.
-
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
11/3/2022
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update and reported third quarter 2022 financial results.
-
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
10/27/2022
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board.
-
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
10/5/2022
NextCure, Inc. today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022.
-
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
10/4/2022
NextCure, Inc. today announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors.
-
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
9/22/2022
NextCure, Inc. (Nasdaq: NXTC today announced that it will present at the Ladenburg Thalmann Healthcare Conference in New York City on Thursday, September 29th at 10 am ET.
-
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
8/4/2022
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2022 financial results and provided a business update.
-
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
7/6/2022
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “Development of an Immunohistochemical Assay for Siglec-15” in Laboratory Investigation.
-
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
6/27/2022
NextCure, Inc. presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.
-
NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
6/22/2022
NextCure, Inc. announced that collaborator Brahm Segal, M.D., of Roswell Park Comprehensive Cancer Center shared nonclinical data from a research study that models the ability of NC410 to block neutrophil-mediated suppression of T cells in a tumor microenvironment at the 24th Translational Research Cancer Centers Consortium Annual Meeting.
-
NextCure to Present at the JMP Securities Life Sciences Conference in June 2022
6/8/2022
NextCure, Inc. announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 15th at 2 pm ET.
-
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
5/5/2022
NextCure, Inc. reported first quarter 2022 financial results and provided a business update.
-
NextCure to Present at the BofA Securities 2022 Healthcare Conference
5/3/2022
NextCure, Inc. today announced that it will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday May 10th at 10:40 am PT.